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Abstract
Background:  African and Asian cohort studies have demonstrated the clinical efficacy of
antiretroviral treatment (ART) in resource-limited settings. However, reports of the long-term
changes in the physical and emotional quality of life (QoL) of patients on ART in these settings are
still scarce. In this study, we assessed the physical and emotional QoL after six and 12 months of
ART of a sample of 268 patients enrolled in South Africa's public-sector ART programme. The
study also tested the impact of the adverse effects of medication on patients' physical and emotional
QoL.
Methods: A stratified random sample of 268 patients undergoing ART was interviewed at baseline
(< 6 months ART) and follow-up (< 12 months ART). A model of the relationships between the
duration of ART, the adverse effects of medication, and physical and emotional QoL (measured
using EUROQOL-5D) was tested using structural equation modelling.
Results: The improved physical and emotional QoL shown at baseline was sustained over the 12-
month study period, because treatment duration was not significantly associated with changes in
the patients' QoL. Physical QoL significantly and positively influenced the patients' emotional QoL
(subjective well-being [SWB]) (β = 0.33, P < 0.01). Longitudinal data showed that patients reported
significantly fewer adverse effects at follow-up than at baseline (β = -0.38, P < 0.001) and that these
adverse effects negatively influenced physical (β = -0.27, P < 0.01) and emotional QoL (β = -0.15, P
< 0.05).
Conclusion: This study provides evidence that the South African public-sector ART programme
is effective in delivering sustained improvement in patient well-being. However, the results should
encourage clinicians and lay health workers to be vigilant regarding the adverse effects of
treatment, because they can seriously affect physical and emotional QoL.
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Background
By reducing the morbidity and mortality associated with
HIV/AIDS, public-sector antiretroviral treatment (ART)
has had a dramatic impact on the quality of life (QoL) of
HIV/AIDS patients in industrialized countries [1-9]. These
treatment regimens have also generated numerous socio-
medical studies [1-4,6,10,11]. The South African Govern-
ment has acknowledged the importance of QoL outcomes
by stipulating in its Comprehensive Plan that 'improve-
ments in patient well-being and quality of life' are the pri-
mary targets of the programme [12]. Although promising,
the QoL outcomes for large-scale public ART programmes
in developing countries are still preliminary [13-16]. As
Ferradini et al. stated, studies of medium- to long-term
cohorts of patients are still scarce and have usually been
performed on very limited numbers of patients [17].
QoL is a multi-dimensional construct [18-20]. Quantita-
tively, it may be considered to have two dimensions: the
physical and emotional [19-23]. In this context, the first
measures the impact of disease on physical QoL by assess-
ing the associated physical and functional limitations. The
second addresses changes in the emotional states of
patients, with an emphasis on mood, depression, and life
satisfaction [24,25]. Compared with the basic physical
outcomes of ART, far less is currently known about the
ways in which and the extent to which ART affects the
emotional QoL of patients, especially those living in
resource-poor settings [4,26-29].
Previous studies by Louwagie et al. (2007) and Wouters et
al. (2007) reported a strong positive association between
the first six months of ART and the emotional and physi-
cal QoL of patients enrolled in South Africa's public-sector
ART programme. The initial months of ART were associ-
ated with significant improvements in physical QoL
[30,31]. Furthermore, patients receiving ART reported sig-
nificantly higher levels of emotional well-being than
patients awaiting treatment. These results indicate that
ART is not only directly associated with emotional QoL,
but is also indirectly associated with emotional QoL via
the mediating variable physical QoL [30,31].
Although these studies have provided important insights
into the impact of the South African public ART pro-
gramme on the QoL of HIV/AIDS patients, they have been
limited by the availability of only baseline data. Both
studies stated that further longitudinal research was
needed to clarify the link between ART and self-reported
physical and emotional health outcomes over time. Fur-
thermore, their cross-sectional designs compared patients
awaiting ART with patients who had been receiving ART
for less than six months. Although symptoms related to
the adverse effects of treatment have been associated with
lower QoL scores [17,32-35], a variable that measures
adverse effects could not be included because patients
awaiting treatment could not report such effects [30].
The first objective of this study was to overcome these
study limitations and extend the current literature by
examining the changes in physical and emotional QoL
(differences between the baseline and the six-month fol-
low-up scores) among patients enrolled in South Africa's
public-sector ART programme. This longitudinal
approach allowed us to address our second objective and
include data on the adverse effects of treatment, because
the literature shows that drug toxicity can have a substan-
tial impact on patients' QoL [17,32-35].
Methods
Data collection
This study is part of an ongoing cohort study of patients
enrolled in the public-sector ART programme in the Free
State Province of South Africa. The research was approved
by the Ethics Committee of the Faculty of Humanities of
the University of the Free State.
The sampling frame consisted of a list of names obtained
from the Provincial Department of Health of adult
patients certified as medically ready to commence ART
(CD4 < 200 cells/μL and/or WHO stage IV) within two
months of the first patient having received his/her treat-
ment. The list distinguished those patients who were
receiving treatment at baseline ('treatment' patients) and
those who were certified as ready to commence treatment
but were not yet receiving it ('non-treatment' patients).
Eighty patients were sampled randomly from this list for
each of the five districts of the province (i.e., Lejweleput-
swa, Motheo, Thabo Mofutsanyana, Fezile Dabi, and
Xhariep), proportional to the number of patients per
clinic and per treatment group (treatment and non-treat-
ment patients). Because there were less than 80 eligible
patients in Xhariep, a census of all treatment and non-
treatment patients was conducted.
A total of 371 study participants were recruited into the
study (268 treated and 103 untreated patients). Only
patients who were undergoing treatment at baseline (n =
268) were included in this study, because it assesses the
impact of ART on the QoL of patients. This study used two
waves of panel data to examine the impact of ART on QoL
in the medium term. At baseline (< 6 months ART),
trained enumerators conducted face-to-face interviews
with 268 treatment patients using a standard question-
naire, after the written consent of all the patients had been
obtained. Approximately six months later (< 12 months
ART), 234 of the original cohort of patients were re-inter-
viewed using an updated version of the questionnaire.BMC Public Health 2009, 9:103 http://www.biomedcentral.com/1471-2458/9/103
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Measures
Figure 1 shows the conceptual model to be tested. The
only exogenous variable is the length of treatment time.
We measured the adverse effects of ART using a construct
that categorized patients as having no adverse effects, mild
adverse effects, or disruptive adverse effects. Incorporating
the severity of the adverse effects is important because
many adverse effects are related to mild toxicity, which
can be treated easily. A wide variety of good measures of
quality exist for use in HIV/AIDS populations when phys-
ical criteria are examined [29,36]. To assess physical QoL
in our study, a latent variable was constructed using Euro-
QoL 5D – a standardized, widely validated and tested
instrument developed by the EuroQoL Group to assess
five generic aspects of current health (mobility, self-care,
limitation of activities, pain, and mood). This instrument
has shown good construct validity in AIDS trials in
resource-poor settings [6,37-41]. Respondents could indi-
cate one of three levels of impairment in each health
domain: none, some/moderate, or extreme. The five items
(and the entire questionnaire) were translated into Afri-
kaans, Xhosa, Zulu, and Sotho. The Afrikaans, Xhosa, and
Zulu versions of the EQ-5D are recognised as official
translations by the EuroQoL Group and have shown
equivalent reliability and validity [30,40,42]. The Sotho
instrument was translated for the purpose of this study
and further research is required to ensure its measurement
validity. The EQ-5D is a generic instrument developed to
describe and evaluate overall health-related QoL. How-
ever, in this study, a distinction was drawn between the
physical and emotional outcomes of ART. The "mood"
item in the EQ-5D assesses an aspect of emotional health
and was not included as an indicator of physical QoL.
Therefore, a latent variable measuring the physical QoL of
patients was constructed using only the first four dimen-
sions of the EQ-5D.
Measures of overall emotional or psychological well-
being are generally based on self-reports. This is called
subjective well-being (SWB) [43-45]. SWB is an important
indicator of QoL because it describes a person's multi-
dimensional evaluation of his/her life, including affective
evaluations of moods and emotions, and cognitive judge-
ments of life satisfaction [45-49]. There is currently a con-
sensus that SWB consists of three primary components:
life satisfaction, pleasant affect, and low levels of unpleas-
ant affect [44,47,48,50,51]. SWB has previously been used
successfully to evaluate people's well-being in South
Africa [30,43,49]. Patient responses to a standard five-
point scaled item regarding overall life satisfaction were
used to measure the cognitive part of SWB. An item asking
about global happiness was used as a measure of positive
emotions. The fifth EuroQoL item, measuring anxiety and
depression, was used to measure the third component of
SWB, the lack of unpleasant affect. This instrument has
shown good reliability and construct validity in earlier
studies of QoL in ART patients in South Africa [30].
Data analysis
Structural equation modelling (SEM) was used to assess
firstly, the influence of ART on physical and emotional
QoL, and secondly, the impact of physical QoL on emo-
tional QoL. This model also included the impact of
adverse treatment effects on the patients' physical and
emotional QoL. SEM is a combination of factor analysis
and path analysis, and is particularly well suited to
addressing longitudinal analytical problems. Unlike mul-
tiple regression models, SEM permits the simultaneous
assessment of multiple dependent variables in a single
model. SEM also allows the examination of both the
direct and indirect effects of one variable on another. Fur-
thermore, with SEM, a given construct can be treated as
both an independent and a dependent variable, providing
a model that more closely parallels the complex nature of
most social and clinical phenomena (path analysis).
Finally, SEM allows the examination of the relationships
among both measured and latent variables (factor analy-
sis), which often provides a more precise measure of com-
plex social phenomena than do single measurements
[52]. All data analysis was performed with the statistical
software package LISREL Version 8.72.
Results
Sample description
The mean age of this sample of people living with HIV/
AIDS was 37.9 years (SD = 8.6). Of the 268 ART patients
included in this study, 66.8% were women. Overall, the
patients described their physical QoL as good or excellent,
with a relatively small improvement over time. The vast
majority of patients had no problems with walking about
(81.3% at baseline, 83.2% at follow-up), with washing or
dressing themselves (94.0% at baseline, 94.8% at follow-
up), or with performing their usual activities (80.6% at
baseline, 85.8% at follow-up). Pain and discomfort were
more common, and approximately four of every 10
respondents (39.6% at baseline, 37.5% at follow-up)
The conceptual model, showing the hypothesized relation- ships between ART duration, adverse effects, and physical  and emotional quality of life (QoL) Figure 1
The conceptual model, showing the hypothesized 
relationships between ART duration, adverse effects, 
and physical and emotional quality of life (QoL).
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reported at least some pain or discomfort. Generally, the
respondents' emotional QoL was also high: 70.1% of
respondents reported no anxiety or depression and 77.6%
of respondents were fairly happy to very happy with their
life in general, showing high levels of positive affect. The
patients' life satisfaction was slightly lower, insofar as
44.0% of patients were dissatisfied to very dissatisfied
with the way their life was going. At follow-up, patients
emotional QoL was slightly better: 74.1% of respondents
were neither anxious nor depressed, 72.4% were fairly
happy to very happy, and only 38.8% were dissatisfied
with their life in general (additional file 1 displays the
descriptive statistics of the sample).
After six moths of ART, 55.1% of patients experienced
some adverse effects of the antiretroviral medication. The
most reported adverse effects were nausea, skin problems,
and dizziness. When we measured the severity of these
adverse effects, 58.9% of patients who reported adverse
effects experienced them as very disruptive. Approxi-
mately six months later, drug substitution and sympto-
matic treatment had resulted in only 27.3% of patients
reporting any adverse effects of treatment. However,
66.7% of these patients experienced these adverse effects
as very disruptive. Between baseline and follow-up, 17.7%
of the patients changed treatments. Of the patients evalu-
ated, 56.0% started treatment with stavudine, lamivudine,
and efavirenz, and 41.8% started treatment with stavu-
dine, lamivudine, and nevirapine. Approximately six
months later, 62.3% of patients were using the efavirenz-
based regimen and only 36.4% were receiving nevirapine-
based first-line ART. A recent clinical study by van Leth et
al. (2005) indicated that both regimens are effective in
patients with advanced HIV disease and that possible dif-
ferences, if they exist, are small [53].
Attrition analysis
The attrition rate of 13% (34 patients) between the two
interviews was mainly caused by death (n = 15), refusal to
be interviewed (n = 8), and our failure to determine the
current whereabouts of the patient (n = 5). Attrition anal-
ysis of the study variables (physical and emotional QoL,
adverse effects) revealed that responders had significantly
better physical and emotional QoL at baseline than those
of non-responders and reported fewer adverse effects than
did non-responders.
Measurement model
Because SEM is a hybrid of factor analysis and path analy-
sis, a two-step approach is recommended. Separate assess-
ments of the measurement and structural models prevent
the good fit of one model compensating for (and poten-
tially masking) the poor fit of the other (additional file 2
displays the correlations among all study variables). Table
1 shows the final measurement model, which has accept-
able practical fit indices. As in our previous study, the
composite reliability shows the excellent consistency of
the indicators in measuring both latent variables: physical
and emotional QoL. The discriminant validity of the con-
structs is supported by the χ2 difference test and the vari-
ance extracted test. Combined, these findings support the
reliability and validity of the two constructs and their indi-
cators.
Structural model
Table 2 summarizes the parameter estimates of the struc-
tural model. The root mean square error of approximation
(RMSEA) indicates the closeness of fit of the overall
model, with reasonable errors of approximation in the
population. Other goodness-of-fit statistics suggest that
the structural model not only fits adequately, but also
withstands the tests of parsimony (RMSEA = 0.0312, com-
parative fit index [CFI] = 0.996, parsimony normed fit
index [PNFI] = 0.630).
Physical and emotional QoL
The model tested the impact of ART on physical and emo-
tional QoL during the second half of the first year of ART.
The first part estimated the direct and indirect effects of
treatment duration on both QoL measures. Firstly, the
treatment variable had no significant impact on physical
QoL, meaning that the additional six months of ART did
not further improve the physical well-being of the
patients. Secondly, patients did not report significantly
higher emotional QoL at follow-up than that at baseline.
However, the lack of a negative impact of treatment dura-
tion on QoL means that the improved QoL following the
start of treatment was maintained at follow-up. Finally,
there was a strong significant positive association between
physical and emotional QoL. The patients' emotional
QoL increased by 0.33 standard deviations when their
physical QoL increased by one standard deviation (P <
0.001).
Adverse effects
Unlike previous studies, this model included the adverse
effects of treatment as a dependent variable on treatment
duration and a predictor of physical and emotional QoL.
Firstly, treatment duration was significantly associated
with the experience of adverse effects (β = -0.38, P  <
0.001). Patients at follow-up reported significantly fewer
adverse effects than did patients at baseline. The amount
of explained variance in the experience of adverse effects
was 0.20. Secondly, the variable measuring adverse effects
had a strong negative impact on physical QoL. The analy-
sis shows that the respondent's physical QoL decreased by
0.27 standard deviations when the patient reported
adverse effects (P < 0.01). The amount of explained vari-
ance in physical QoL was 0.15. Finally, these results indi-
cate that adverse effects were also negatively associated
with the emotional well-being of ART patients. The signif-
icant path coefficient of -0.15 implies that their emotionalBMC Public Health 2009, 9:103 http://www.biomedcentral.com/1471-2458/9/103
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Table 1: Item analysis, goodness-of-fit, and reliability assessment of the measurement model (n = 268)
Scale Standardized Loadings1 t Value
Physical QoL
Mobility 0.787*** 13.883
Usual activities 0.936*** 34.920
Pain 0.829*** 20.995
Self-care 0.938*** 23.281
Emotional QoL
Satisfaction with life 0.730*** 10.561
Pleasant affect 0.946*** 11.394
Absence of unpleasant affect 0.798*** 7.975
Test for Fit Measurement Model Criteria for Good Fit
RMSEA 0.0312 < 0.05
Normed Fit Index (NFI) 0.985 > 0.9
Non-Normed Fit Index (NNFI) 0.993 > 0.9
Comparative Fit Index (CFI) 0.996 > 0.9
Reliability Criteria for Reliability
Composite reliability (Phys. QoL) 0.892 > 0.7
Composite reliability (Emo. QoL) 0.829 > 0.7
Validity Criteria for Validity
χ2 difference test 42.115 (1); P < 0,001 P < 0.05
Extracted variance test (Phys. QoL) 0.881 > 0.5
Extracted variance test (Emo. QoL) 0.812 > 0.5
*** P < 0.001
1The standardized factor loading is the standardized regression coefficient of the latent variable on the indicator (the measured variable). Squaring 
the factor loading gives us the percentage of variance of the measured variable explained by the latent variable.
Table 2: Standardized LISREL coefficients and summary of the structural model (n = 268)
Path Path Coefficient t Value
ARV Treatment Duration → Adverse Effects -0.38*** -6.031
Adverse Effects → Physical QoL -0.27** -2.729
Adverse Effects → Emotional QoL -0.15* -1.966
ARV Treatment Duration → Physical QoL -0.03a -0.329
ARV Treatment Duration → Emotional QoL -0.08a -0.761
Physical QoL → Emotional QoL 0.33** 2.971
Test for Fit Structural Model Criteria for Good Fit
RMSEA1 0.0312 < 0.05
Normed Fit Index (NFI) 0.985 > 0.90
Non-Normed Fit Index (NNFI) 0.993 > 0.90
Comparative Fit Index (CFI) 0.996 > 0.90
Parsimony Goodness of Fit Index (PGFI) 2 0.433
Parsimony Normed Fit Index (PNFI) 2 0.630
a Not statistically significant. * P < 0.05, ** P < 0.01, *** P < 0.001
1RMSEA, root mean square error of approximation. RMSEA is a measure of the discrepancy per degree of freedom for the model and reflects 
badness-of-fit per degree of freedom. A value for RMSEA of 0.05 or less indicates a close fit of the model in relation to the degrees of freedom.
2These fit indices are relative fit indices that are adjustments of the goodness of fit index (GFI) and the normed fit index (NFI). The adjustments are 
made to penalize the models that are less parsimonious, so that simpler theoretical models are favoured over more complex ones. Although no 
threshold levels have been recommended for these indices, higher values are preferable.BMC Public Health 2009, 9:103 http://www.biomedcentral.com/1471-2458/9/103
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QoL increased by 0.15 standard deviations in the absence
of adverse effects. The squared multiple correlation coeffi-
cient, R2, for the structural equation predicting emotional
QoL was 0.40, indicating that 40% of the variation in
emotional QoL can be explained by ART, the associated
physical health benefits, and the absence of adverse
effects.
Discussion
This study assessed the physical and emotional QoL in a
sample of 268 patients enrolled in South Africa's public-
sector ART programme after six and 12 months. Overall,
the physical and emotional QoL of the respondents were
high and the improved physical and emotional QoL that
were demonstrated in previous studies were sustained
over the 12-month study period. Such favourable QoL
outcomes are similar to those reported in industrialized
societies [3,7,9,31,54-56]. This longitudinal study pro-
vides evidence that the South African public-sector ART
programme is effective in delivering sustained improve-
ments in patient well-being, confirming universal treat-
ment access as a key policy priority.
This study also evaluated the impact of the adverse effects
of medication on the patients' physical and emotional
QoL. Adverse effects to ART significantly and negatively
influenced patients' physical and emotional QoL. How-
ever, our longitudinal data showed that patients reported
significantly fewer adverse effects at follow-up than at
baseline. The most cited adverse effects (dizziness, nausea,
and skin problems) are related to mild toxicity, which
does not require the discontinuation of therapy or drug
substitution (17.7% of patients changed treatments) and
can be overcome by symptomatic treatment [57].
Despite favourable QoL outcomes, two considerations
leave little room for complacency. The first one emerges
when we link the lack of additional improvement in QoL
to the reduction in adverse effects following early drug
toxicity. In contradiction to the suggestion of Liu et al.
(2006), the lack of additional long-term effects on QoL
does not reflect a balance between reduced HIV-related
symptoms and additional adverse effects from ART [35].
All other things being equal, a reduction in drug toxicity
would be expected to result in a further improvement in
QoL. Mannheimer et al. (2005) suggested that pill fatigue
causes a decline in adherence levels, which is related to
lower levels of physical and emotional QoL [3]. Further
research is required to understand the cause of the lack of
further QoL improvement when the adverse effects of ART
decrease over time. Secondly, our results indicate a strong
negative association between the adverse effects of ART
and the physical and emotional QoL of patients.
Although our results suggest a decline in adverse effects
over time, other research has shown that many adverse
effects of treatment only develop in the later stages of
treatment (e.g., lipoatrophy) [57-61]. These results should
encourage clinicians and lay health workers to be vigilant
regarding the adverse effects of treatment, because they
can seriously affect emotional and physical QoL.
Strengths and limitations
The strengths of this study include its longitudinal charac-
ter and the availability of information on an understudied
population. However, it has some limitations. Because of
the limited generalizability of the study findings, we can
only ascribe the outcomes to patients enrolled in a public-
sector ART programme and, more specifically, to patients
enrolled in South Africa's Free State Province ART pro-
gramme. Secondly, although the analysis focused on the
impact of treatment duration and adverse effects on phys-
ical and emotional QoL, the structural equation model
offers an incomplete explanation of the patients' QoL.
Patient characteristics (age, sex) and socio-economic traits
(education level and income) were tested as predictors of
the patients' QoL but did not improve the model signifi-
cantly. Other potentially relevant predictors of QoL (e.g.,
ART adherence, symptomatic interventions, and co-treat-
ments) were not available in the data set.
Conclusion
Although our knowledge of the complex relationships
between ART and the multi-dimensional construct QoL in
a resource-poor setting is still in its infancy, these analyses
have both practical and theoretical implications. Theoret-
ically, this study contributes to our understanding of the
impact of ART on the different dimensions of QoL of
patients enrolled in a public-sector ART programme in a
resource-limited setting. Physical QoL and the adverse
effects of treatment have a significant impact on emo-
tional QoL, which draws greater attention to the emo-
tional dimension of ART health outcomes. This research
shows that emotional QoL correlates with physical health
measures, but cannot be reduced to a mere component of
physical QoL. Therefore, the general focus of research on
physical outcomes is too narrow.
In practical terms, this study has shown that HIV patients
enrolled in South Africa's public sector ART programme
have similar QoL outcomes to those of patients in indus-
trialized settings. The improvement in QoL was also sus-
tained throughout the 12-month study period, indicating
the medium-term efficacy of a public-sector ART pro-
gramme in a high-prevalence, resource-limited setting.
However, vigilance is needed because our findings show
that the adverse effects of treatment can significantly
reduce the chance of a successful ART scale-up. Further
research is required to inform policy-makers of how to
maximize the benefits of ART in the context of a massive
epidemic and an often overstretched health system.BMC Public Health 2009, 9:103 http://www.biomedcentral.com/1471-2458/9/103
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